FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 552 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Spending Review 2020 – Steps in the right direction, but opportunities... November 25, 2020 Reflections from our chief clinician: The essential role of our research... February 4, 2022 Five Questions With…Jim. April 28, 2022 Imaging Test Could Help Guide Breast Cancer Treatment Decisions March 11, 2021 Load more HOT NEWS FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for... Maintenance Therapy with CC-486 Extends Survival of Adults with AML Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced...
